71 results about "Prostasomes" patented technology

The present invention provides fluorinated pyrrolo[2,3,d]pyrimidine nucleoside compounds which are inhibitors of RNA-dependent RNA viral polymerase. These compounds are inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as precursors to inhibitors of hepatitis C virus (HCV) NS5B polymerase, as precursors to inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compositions containing such fluorinated pyrrolo[2,3-d]pyrimidine nucleoside alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the fluorinated pyrrolo[2,3-d]pyrimidine nucleoside of the present invention.

This invention provides populations of neural cells bearing markers of glial cells, such as oligodendrocytes and their precursors. The populations are generated by differentiating pluripotent stem cells such as human embryonic stem cells under conditions that promote enrichment of cells with the desired phenotype or functional capability. Various combinations of differentiation factors and mitogens can be used to produce cell populations that are over 95% homogeneous in morphological appearance, and the expression of oligodendrocyte markers such as GalC. The cells are capable of forming myelin sheaths, and can be used therapeutically improve function of the central nervous system.

The present invention relates to the use of matrix metalloproteinase 7 (MMP-7) and/or its precursors and fragments with MMP-7 immunoreactivity, or of circulating anti-MMP-7 antibodies, as humoral biomarkers in diagnostic in vitro methods for the detection, early detection, monitoring and/or prognosis of renal cell carcinoma (RCC) in human patients.

The invention relates to the immunoassay medical field, in particularly provides a chemiluminescence immunoassay test kit and a preparing method thereof for pro gastrin releasing peptide (31-98). Through adopting Biotin-Streptoavidin system coated antibody, the invention can improve antibody coating efficiency, and can improve the sensitivity at the same time. The test kit provides diagnosis of small-cell lung cancer with accurate chemiluminescence test kit which has simple operation and sensitive result detecting, so as to meet the requirements in clinical diagnosis.

The generation of complex organ tissues from human embryonic and pluripotent stem cells (PSCs) remains a major challenge for translational studies. It is shown that PSCs can be directed to differentiate into intestinal tissue in vitro by modulating the combinatorial activities of several signaling pathways in a step-wise fashion, effectively recapitulating in vivo fetal intestinal al development. The resulting intestinal “organoids” were three-dimensional structures consisting of a polarized, columnar epithelium surrounded by mesenchyme that included a smooth muscle-like layer. The epithelium was patterned into crypt-like SOX9-positive proliferative zones and villus-like structures with all of the major functional cell types of the intestine. The culture system is used to demonstrate that expression of NEUROG3, a pro-endocrine transcription factor mutated in enteric anendocrinosis is sufficient to promote differentiation towards the enteroendocrine cell lineage. In conclusion, PSC-derived human intestinal tissue should allow for unprecedented studies of human intestinal development, homeostasis and disease.

In vitro methods are disclosed that rely on a novel phenomenon of secondary sprouting by cultured endothelial precursor cells, after angiogenic-like tube formation and collapse have occurred on a basement membrane matrix. Particularly disclosed is an in vitro method of isolating and expanding, from a mixed population of mammalian cells originating from a tissue sample, a cellular population enriched for endothelial sprout cells, including cells having one or more physiological and/or immunological features of endothelial precursor cells. Also disclosed is an in vitro method for a screening a substance for potential proangiogenic or antiangiogenic activity.

The invention discloses a method for purifying preadipocytes derived from fetal bovine skeletal muscle tissue. According to the method, a used material is longissimus dorsi tissue of a 3-month-old bovine fetus, and used reagents contain collagenase, fetal bovine serum, the low- glucose Dulbecco's Modified Eagle's Medium, a cell sorting buffer solution, a PDGFR-alpha (platelet-derived growth factor receptor alpha) antibody, dexamethasone, 3-isobutyl-1-methylxanthine, bovine insulin and oil red O.

The invention relates to a method for inducing a human pluripotent stem cell to differentiate into an RPE cell. According to the method, an inhibitor is used for inducing the human pluripotent stem cell to differentiate into a neural precursor; after Shh, IGF1 and EGF growth factors are utilized to activate ERK 1/2, JNK, Sonic hedgehog signal routes, the cell is presented as the shape of neuroepithelium, Activen A and Chir99021 are added to activate TGFbeta and Wnt signal routes respectively to induce a neuro-epithelial cell into a retinal progenitor cell; adherent culture is conducted on theretinal progenitor cell to obtain an RPE cell at an underdeveloped state. The invention further studies the field of applying the underdeveloped RPE cell to treating retinal degenerative diseases. Compared with the prior art, the method firstly makes three stages of differentiating the human pluripotent stem cell to the underdeveloped RPE cell and related small molecular substances and growth factors used therein clear. Compared with a matured RPE, the underdeveloped RPE obtained through differentiation can treat the retinal degenerative diseases more effectively after being transplanted.

The invention discloses a culture method of vascular endothelial progenitor cells, which comprises the following steps: 1) inducing differentiation of multipotent stem cells in a culture medium A to form mesendoderm precursor cells; and 2) inducing differentiation of the mesendoderm precursor cells in a culture medium B to form the vascular endothelial progenitor cells. The culture medium A contains a DMEM (dulbecco's modified eagle medium) culture medium, an F12 culture medium, sodium selenate, sodium bicarbonate, vitamin C, insulin, activin A, a bone formation protein 4 and a glycogen synthetase kinase-3 inhibitor. The culture medium B contains a DMEM culture medium, an F12 culture medium, vitamin C, insulin, a vascular endothelial growth factor and a transforming growth factor beta signal pathway inhibitor. The culture media used in the culture method do not contain any animal-derived component, and can provide sufficient nutrient substances and stable living environments for the cultured cells, thereby efficiently inducing the differentiation of the human multipotent stem cells to form the vascular-grid vascular endothelial progenitor cells which are highly similar to the human cord vessel endothelial cells.

Methods for quantifying an HPV protein expression in a clinical sample are disclosed. The quantifying methods include the process for obtaining the clinical sample. Such a clinical sample is consisted of a population of cells that are susceptible to infection by an HPV. The quantifying methods also include the process for depositing the clinical sample into a container. The clinical sample is contacted with the first antibody that specifically binds to an HPV protein which is expressed by an HPV-infected cell under a condition that promotes specific binding of the first antibody to the HPV protein expressed by the population of cells. The methods further include the process for quantifying the specific binding of the first antibody and thereby quantifying the HPV protein expression in the clinical sample. The assay provides an objective test to identify patients with high-grade precursor from cytology samples before biopsy.

Compositions comprising stem cells delivered into infarcted myocardium by endocardial injection, engraft and differentiate into myocytes, endothelial cells, and vascular smooth muscle, and do so without the requirement for survival enhancing modification. These cells engraft whether injected acutely (days) or late (months) after myocardial infarction, and the efficiency of engraftment correlates with the functional recovery of the heart. The stem cells also recruit endogenous cardiac precursor cells, reconstitute myocardial stem cell niches, and enhance endogenous cell differentiation into myocytes.

The invention discloses an immunologic tolerance dendritic cell, a preparation method thereof and a special culture medium. The culture medium is formed by the way that mesenchyma stem cells are added into a dendritic cell culture medium. The preparation method comprises: the precursors and the inducible factors of dendritic cells are added into the culture medium. The co-culture proportion of the mesenchyma stem cells to the dendritic cells is (1-2) to (1-10), preferably 1 to 1; the precursors of the dendritic cells are CD34 cells; and the inducible factors comprise GM-CSF, TNF- alpha, IL-4 and LPS. The invention provides the application of the immunologic tolerance dendritic cell during preparing immunologic tolerance medicine for organisms. The immunologic tolerance dendritic cell can lowly express co-stimulatory molecule, reduce inflammatory factors, increase the secretion of suppressor cytokines, have vasculogenesis activity, and inhibit the multiplication of variant T cells. The invention has the advantages of simple operation, convenience and practicality, and establishes a stable culture technical system for selective activation dendritic cells.

The invention discloses a gastrin-releasing peptide precursor diluent, and an application and a kit thereof. The gastrin-releasing peptide precursor diluents includes: 0.01-0.5 mol/L of one or two buffer solutions including citric acid-sodium citrate and citric acid-disodium hydrophosphate, 50-500 mmol/L of inorganic salt, and 0.01-0.5% w/w of a preservative. The gastrin-releasing peptide precursor diluent is used for preparing a calibrator and a quality control substance of gastrin-releasing peptide precursor. The gastrin-releasing peptide precursor detection kit contains the gastrin-releasing peptide precursor calibrator and quality control substance, which are prepared from the gastrin-releasing peptide precursor diluent; the gastrin-releasing peptide precursor diluent not only ensuresthat a gastrin-releasing peptide precursor antigen can be preserved at 2-8 DEG C for a long time under liquid status, but also significantly increase the thermostability of the gastrin-releasing peptide precursor antigen under liquid-state preservation at 37 DEG C.

The present invention provides methods and compositions to reduce immune tolerance at specific sites. In one aspect, the present invention comprises methods and compositions to reduce tumorigenicity. In an embodiment, the present invention reduces recruitment of tolerance-inducing antigen presenting cells (APCs) or their precursors to a tumor and/or tumor draining lymph node by decreasing binding of at least one tumor-associated ligand to a chemokine receptor present on the tolerance-inducing APCs or APC precursors. In an embodiment, the chemokine receptor is CCR6 and the tumor-associated ligand is mip-3α. In another aspect, the present invention comprises methods and compositions to reduce immune tolerance to a virus. In an embodiment, the virus is HIV. The present invention further provides for the development of CCR6 antibodies and antagonists as therapeutic agents to prevent or reduce immune tolerance.

Methods for determining the sensitizing, irritant and/or allergenic potential of a candidate substrate are provided. These methods involve simultaneously cultivating keratinocytes and Langerhans cell precursors in a nutrient medium in order to effect differentiation of the Langerhans cell precursors, and contacting the candidate substrate with the cultured cells to determine the effect if any on markers associated with sensitizing, irritant or allergenic potential.

The invention discloses the use of a compound and the drug composite of the compound in the preparation of a therapeutic drug or an ancillary therapeutic drug for diseases related to the disorder of transcription factor or ancillary factor of the transcription factor. The compound is the compound shown in the formula (I), the Z-A-Z' or the pharmacologically acceptable salt or prodrug. The use of the compound has the beneficial effects that the micromolecule compound provided by the invention is derived from pair transcription factors, such as the analysis of foxp P3 and/or myocyte enhancement factor 2 molecular structure and the interaction locus of the binding protein of the foxp P3 and/or the myocyte enhancement factor 2 molecular structure. Therefore, the micromolecule compounds can be used for adjusting the function of the related transcription factor, wherein the function comprises the interaction influencing the relevant transcription factor and the binding protein comprising various transcription factors. Due to the function adjustment of the foxp P3 and/or the myocyte enhancement factor 2, the micromolecule compounds have obvious drug and treatment uses to the malignant tumor, in particular to the treatment of the malignant tumor such as the carcinoma of uterine cervix, the breast cancer and the like, so that the animal experiment shows that the compound is extremely good in inhibition effect.

The invention provides a method for induced differentiation of human amniotic mesenchyme cells in vitro into insulin-secreting cells. The steps include: isolation culture of primary cells; purification of primary cells; primary cell identification by a flow cytometer; 2-mercaptoethanol, B27, bFGF, and nicotinamide induction; and cell morphology and function identification after induction. The method for induced differentiation of human amniotic mesenchyme cells in vitro into insulin-secreting cells provided by the invention induces human amniotic mesenchymal cells to differentiate into nestin positive cells, induces nestin positive cell amplification and differentiation into precursor cells, and induces insulin-secreting cell maturation, confirms that amniotic mesenchyme cells have the possibility of transformation into insulin-secreting cells in specific environment, amniotic mesenchyme cells have wide sources, and no ethical obstacle exists, therefore the method provides a new idea for clinical stem cell transplantation.

The invention discloses an application of gastrodin for preventing and treating osteoporosis, gastrodin has nontoxic effect to osteoblast precursor cells, and has no influence on cell proliferation; gastrodin has protection effect on apoptosis of MC3T3-E1 caused by hydrogen peroxide; improves oxidative stress state induced by H2O2 in a differentiation process of the MC3T3-E1, and has protective function on MC3T3-E1 osteogenic differentiation inhibition caused by H2O2; besides, gastrodin can inhibit expression of a bone absorption factor. Therefore, gastrodin can play a role of protecting osteoporosis through improvement on osteoblast apoptosis and differentiation inhibition, and indirect inhibition of osteoclast activation. In an osteoporosis model of castrated mice, gastrodin can improve oxidative stress state in serum, improves a bone micro-structure of cancellous bone of distal femur and lumbar vertebra, and increases osteogenesis rate of distal femur, so that gastrodin can improve bone micro-structure by inhibiting the oxidative stress state and has the effect for preventing and treating osteoporosis.